comparemela.com
  1. Home
  2. Live Updates
  3. Chidamide Tucidinostat - Breaking News

Latest Breaking News On - Chidamide tucidinostat - Page 1 : comparemela.com

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

/PRNewswire/ Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company s lead innovative.

Feng wangUnited statesRuihua xuSun yatXianping luChidamide tucidinostatChipscreen biosciencesWeili zhaoChidamide epidazaData monitoring committeeChipscreen biosciences united states co ltdPrnewswire shenzhen chipscreen biosciences co ltdChengdu small molecule early rd centerShanghai jiao tong university school of medicineChengdu regional head office rd centerShenzhen chipscreen biosciences co ltd

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan

/PRNewswire/ Shenzhen Chipscreen Biosciences licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide.

Kensei tobinaiChidamide tucidinostatChipscreen bioscienceChipscreen biosciencesLu xianpingMireille gillingsHuya internationalMinistry of healthUnited stateShenzhen chipscreen biosciences co ltdScientist of the national cancer center hospitalShenzhen chipscreen bioscienceVisiting scientistNational cancer center hospitalChidamide phaseObjective response rate

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan

/PRNewswire/ Shenzhen Chipscreen Biosciences licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide.

Kensei tobinaiChidamide tucidinostatChipscreen bioscienceChipscreen biosciencesLu xianpingMireille gillingsHuya internationalMinistry of healthUnited stateShenzhen chipscreen biosciences co ltdScientist of the national cancer center hospitalShenzhen chipscreen bioscienceVisiting scientistNational cancer center hospitalChidamide phaseObjective response rate

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.